HER2 status, evaluated by in situ hybridization (ISH) or IHC, is the primary predictor of responsiveness to HER2-targeted therapies and can determine the benefit from adjuvant trastuzumab therapy in breast cancer [25]. The gene discussed is ERBB2; the disease is breast cancer.